Core Viewpoint - The company has completed the first patient dosing in a Phase II clinical trial evaluating the combination of Tinengotinib with Kanfang Biotech's anti-cancer drugs for advanced hepatocellular carcinoma [1][2] Group 1: Clinical Trial Details - The trial is an open-label, multicenter Phase II study conducted in China, aimed at assessing the efficacy and safety of Tinengotinib in combination with Kanfang's drugs, Kadyuoni (PD-1/CTLA-4) and Yidafang (PD-1/VEGF) [2] - The primary objective of the trial is to evaluate the safety and effectiveness of the combination therapies compared to Tinengotinib monotherapy in patients with advanced hepatocellular carcinoma who have not received prior systemic anti-tumor treatment or have failed standard treatment [2] Group 2: Collaboration and Development - The company has established a collaboration agreement with Kanfang Biotech to jointly develop clinical combination therapies in the field of hepatocellular carcinoma [2]
药捷安康-B(02617)：替恩戈替尼联用康方生物开坦尼®(卡度尼利，PD-1/CTLA-4)╱ 依达方®(依沃西，PD-1/VEGF)的II期临床试验完成首例患者给药